A paracrine role for il6 in prostate cancer patients: Lack of production by primary or metastatic tumor cells

Shu Han Yu, Qizhi Zheng, David Esopi, Anne Macgregor-Das, Jun Luo, Emmanuel Antonarakis, Charles G. Drake, Robert Vessella, Colm Morrissey, Angelo Michael Demarzo, Karen Sfanos

Research output: Contribution to journalArticle

Abstract

Correlative human studies suggest that the pleiotropic cytokine IL6 contributes to the development and/or progression of prostate cancer. However, the source of IL6 production in the prostate microenvironment in patients has yet to be determined. The cellular origin of IL6 in primary and metastatic prostate cancer was examined in formalin-fixed, paraffin-embedded tissues using a highly sensitive and specific chromogenic in situ hybridization (CISH) assay that underwent extensive analytical validation. Quantitative RTPCR showed that benign prostate tissues often had higher expression of IL6 mRNA than matched tumor specimens. CISH analysis further indicated that both primary and metastatic prostate adenocarcinoma cells do not express IL6 mRNA. IL6 expression was highly heterogeneous across specimens and was nearly exclusively restricted to the prostate stromal compartment-including endothelial cells and macrophages, among other cell types. The number of IL6-expressing cells correlated positively with the presence of acute inflammation. In metastatic disease, tumor cells were negative in all lesions examined, and IL6 expression was restricted to endothelial cells within the vasculature of bone metastases. Finally, IL6 was not detected in any cells in soft tissue metastases. These data suggest that, in prostate cancer patients, paracrine rather than autocrine IL6 production is likely associated with any role for the cytokine in disease progression.

Original languageEnglish (US)
Pages (from-to)1175-1184
Number of pages10
JournalCancer immunology research
Volume3
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Interleukin-6
Prostatic Neoplasms
Neoplasms
Prostate
In Situ Hybridization
Endothelial Cells
Cytokines
Neoplasm Metastasis
Messenger RNA
Paraffin
Formaldehyde
Disease Progression
Adenocarcinoma
Macrophages
Inflammation
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

A paracrine role for il6 in prostate cancer patients : Lack of production by primary or metastatic tumor cells. / Yu, Shu Han; Zheng, Qizhi; Esopi, David; Macgregor-Das, Anne; Luo, Jun; Antonarakis, Emmanuel; Drake, Charles G.; Vessella, Robert; Morrissey, Colm; Demarzo, Angelo Michael; Sfanos, Karen.

In: Cancer immunology research, Vol. 3, No. 10, 01.10.2015, p. 1175-1184.

Research output: Contribution to journalArticle

Yu, Shu Han ; Zheng, Qizhi ; Esopi, David ; Macgregor-Das, Anne ; Luo, Jun ; Antonarakis, Emmanuel ; Drake, Charles G. ; Vessella, Robert ; Morrissey, Colm ; Demarzo, Angelo Michael ; Sfanos, Karen. / A paracrine role for il6 in prostate cancer patients : Lack of production by primary or metastatic tumor cells. In: Cancer immunology research. 2015 ; Vol. 3, No. 10. pp. 1175-1184.
@article{1fb60ec3325b4bdc95b8bf8dea02c55f,
title = "A paracrine role for il6 in prostate cancer patients: Lack of production by primary or metastatic tumor cells",
abstract = "Correlative human studies suggest that the pleiotropic cytokine IL6 contributes to the development and/or progression of prostate cancer. However, the source of IL6 production in the prostate microenvironment in patients has yet to be determined. The cellular origin of IL6 in primary and metastatic prostate cancer was examined in formalin-fixed, paraffin-embedded tissues using a highly sensitive and specific chromogenic in situ hybridization (CISH) assay that underwent extensive analytical validation. Quantitative RTPCR showed that benign prostate tissues often had higher expression of IL6 mRNA than matched tumor specimens. CISH analysis further indicated that both primary and metastatic prostate adenocarcinoma cells do not express IL6 mRNA. IL6 expression was highly heterogeneous across specimens and was nearly exclusively restricted to the prostate stromal compartment-including endothelial cells and macrophages, among other cell types. The number of IL6-expressing cells correlated positively with the presence of acute inflammation. In metastatic disease, tumor cells were negative in all lesions examined, and IL6 expression was restricted to endothelial cells within the vasculature of bone metastases. Finally, IL6 was not detected in any cells in soft tissue metastases. These data suggest that, in prostate cancer patients, paracrine rather than autocrine IL6 production is likely associated with any role for the cytokine in disease progression.",
author = "Yu, {Shu Han} and Qizhi Zheng and David Esopi and Anne Macgregor-Das and Jun Luo and Emmanuel Antonarakis and Drake, {Charles G.} and Robert Vessella and Colm Morrissey and Demarzo, {Angelo Michael} and Karen Sfanos",
year = "2015",
month = "10",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0013",
language = "English (US)",
volume = "3",
pages = "1175--1184",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - A paracrine role for il6 in prostate cancer patients

T2 - Lack of production by primary or metastatic tumor cells

AU - Yu, Shu Han

AU - Zheng, Qizhi

AU - Esopi, David

AU - Macgregor-Das, Anne

AU - Luo, Jun

AU - Antonarakis, Emmanuel

AU - Drake, Charles G.

AU - Vessella, Robert

AU - Morrissey, Colm

AU - Demarzo, Angelo Michael

AU - Sfanos, Karen

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Correlative human studies suggest that the pleiotropic cytokine IL6 contributes to the development and/or progression of prostate cancer. However, the source of IL6 production in the prostate microenvironment in patients has yet to be determined. The cellular origin of IL6 in primary and metastatic prostate cancer was examined in formalin-fixed, paraffin-embedded tissues using a highly sensitive and specific chromogenic in situ hybridization (CISH) assay that underwent extensive analytical validation. Quantitative RTPCR showed that benign prostate tissues often had higher expression of IL6 mRNA than matched tumor specimens. CISH analysis further indicated that both primary and metastatic prostate adenocarcinoma cells do not express IL6 mRNA. IL6 expression was highly heterogeneous across specimens and was nearly exclusively restricted to the prostate stromal compartment-including endothelial cells and macrophages, among other cell types. The number of IL6-expressing cells correlated positively with the presence of acute inflammation. In metastatic disease, tumor cells were negative in all lesions examined, and IL6 expression was restricted to endothelial cells within the vasculature of bone metastases. Finally, IL6 was not detected in any cells in soft tissue metastases. These data suggest that, in prostate cancer patients, paracrine rather than autocrine IL6 production is likely associated with any role for the cytokine in disease progression.

AB - Correlative human studies suggest that the pleiotropic cytokine IL6 contributes to the development and/or progression of prostate cancer. However, the source of IL6 production in the prostate microenvironment in patients has yet to be determined. The cellular origin of IL6 in primary and metastatic prostate cancer was examined in formalin-fixed, paraffin-embedded tissues using a highly sensitive and specific chromogenic in situ hybridization (CISH) assay that underwent extensive analytical validation. Quantitative RTPCR showed that benign prostate tissues often had higher expression of IL6 mRNA than matched tumor specimens. CISH analysis further indicated that both primary and metastatic prostate adenocarcinoma cells do not express IL6 mRNA. IL6 expression was highly heterogeneous across specimens and was nearly exclusively restricted to the prostate stromal compartment-including endothelial cells and macrophages, among other cell types. The number of IL6-expressing cells correlated positively with the presence of acute inflammation. In metastatic disease, tumor cells were negative in all lesions examined, and IL6 expression was restricted to endothelial cells within the vasculature of bone metastases. Finally, IL6 was not detected in any cells in soft tissue metastases. These data suggest that, in prostate cancer patients, paracrine rather than autocrine IL6 production is likely associated with any role for the cytokine in disease progression.

UR - http://www.scopus.com/inward/record.url?scp=84962407508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962407508&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0013

DO - 10.1158/2326-6066.CIR-15-0013

M3 - Article

C2 - 26048576

AN - SCOPUS:84962407508

VL - 3

SP - 1175

EP - 1184

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 10

ER -